Insulet to Present at Upcoming Investor Conferences
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will present at three virtual investor conferences. The events include the Canaccord Genuity 2020 MedTech & Diagnostics Forum on November 19, the Piper Sandler 32nd Annual Healthcare Conference on November 23, and the Nasdaq 43rd Investor Conference on December 2. Live audio webcasts of the presentations will be available on the Insulet investor website, with replays following each event.
Insulet aims to simplify diabetes management through its Omnipod Insulin Management System.
- None.
- None.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at three upcoming virtual investor conferences:
- The Canaccord Genuity 2020 MedTech & Diagnostics Forum on Thursday, November 19, 2020, at 12:30 p.m. (Eastern Time)
- The Piper Sandler 32nd Annual Healthcare Conference – the presentation will be available for viewing on Monday, November 23, 2020
- The Nasdaq 43rd Investor Conference on Wednesday, December 2, 2020, at 11:30 a.m. (Eastern Time)
To listen to live audio webcasts of the presentations, please visit http://investors.insulet.com. Replays of the webcasts will also be available following the events.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.omnipod.com.
